(Reuters) – Pfizer Inc and BioNTech SE have proposed to the U.S Food and Drug Administration (FDA) to expand the enrollment of their Phase 3 pivotal COVID-19 vaccine trial to up to about 44,000 participants, the companies said on Saturday.
The initial target figure for the trial was up to 30,000 participants.
(Reporting by Shubham Kalia; Editing by Chizu Nomiyama)
